SMMT earnings analysis
What we found in SMMT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Summit Therapeutics reported a significant net loss of $189.4 million for Q1 2026, exacerbated by rising operational and R&D expenses primarily due to ongoing clinical trials for ivonescimab. Operating expenses rose to $195.2 million, driven largely by an 83% increase in R&D costs. The company continues to face cash flow challenges with a severe cash burn rate amid ongoing development efforts, leading to substantial concerns about liquidity going forward.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Analysis
- Revenue remains undisclosed as of this quarter; however, estimated revenue for Q1 2026 is projected at $40.85 million.
- Dramatic Increase in Operating Expenses
- Total operating expenses soared to $195.2 million, up 192% year-over-year from $66.8 million in Q1 2025.
- Significant R&D Investment
- R&D expenses surged by 159% to $132.6 million from $51.2 million year-over-year, reflecting increased clinical trial activities.
- Cash and Investments Outlook
- As of March 31, 2026, the company reported cash and equivalents of $106.5 million, indicating tightened liquidity.
- Increased Stock-Based Compensation
- Stock-based compensation soared to $72.8 million, up from $11.1 million in Q1 2025, contributing to higher general and administrative expenses.
- Clinical Trials Progress
- Enrollment for HARMONi-3 completed in Q1 2026 while the company anticipates further clinical development in advanced NSCLC and CRC.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Burn Rate
- Net cash used in operating activities was $122.3 million, raising concerns about sustaining operations long-term.
- Substantial Doubt about Going Concern
- The cash and equivalents are insufficient to fund operations for the next 12 months without raising additional capital.
- Dependency on Clinical Trials
- Continued reliance on the clinical success of ivonescimab poses risks as the company lacks FDA approval yet and has incurred heavy expenses.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.24
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SMMT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever